Royal Bank of Canada’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-900
| Closed | -$138K | – | 6818 |
|
|
2024
Q4 | $138K | Hold |
900
| – | – | ﹤0.01% | 5119 |
|
|
2024
Q3 | $174K | Buy |
+900
| New | +$188K | ﹤0.01% | 4924 |
|
|
2022
Q2 | – | Sell |
-1,900
| Closed | -$400K | – | 7371 |
|
|
2022
Q1 | $400K | Sell |
1,900
-3,100
| -62% | -$674K | ﹤0.01% | 4450 |
|
|
2021
Q4 | $1.2M | Hold |
5,000
| – | – | ﹤0.01% | 3623 |
|
|
2021
Q3 | $1.42M | Sell |
5,000
-900
| -15% | -$295K | ﹤0.01% | 3373 |
|
|
2021
Q2 | $2.04M | Sell |
5,900
-41,900
| -88% | -$12.7M | ﹤0.01% | 3050 |
|
|
2021
Q1 | $13.4M | Sell |
47,800
-16,200
| -25% | -$4.37M | ﹤0.01% | 1546 |
|
|
2020
Q4 | $15.7M | Buy |
64,000
+3,000
| +5% | +$774K | ﹤0.01% | 1407 |
|
|
2020
Q3 | $17.3M | Hold |
61,000
| – | – | 0.01% | 1175 |
|
|
2020
Q2 | $16.3M | Buy |
61,000
+7,500
| +14% | +$2.25M | 0.01% | 1156 |
|
|
2020
Q1 | $16.9M | Sell |
53,500
-17,000
| -24% | -$5.16M | 0.01% | 1002 |
|
|
2019
Q4 | $20.9M | Sell |
70,500
-200
| -0.3% | -$55.5K | 0.01% | 1142 |
|
|
2019
Q3 | $16.5M | Sell |
70,700
-2,800
| -4% | -$652K | 0.01% | 1207 |
|
|
2019
Q2 | $17.2M | Buy |
73,500
+12,700
| +21% | +$2.93M | 0.01% | 1213 |
|
|
2019
Q1 | $14.4M | Sell |
60,800
-200
| -0.3% | -$63K | 0.01% | 1282 |
|
|
2018
Q4 | $18.4M | Hold |
61,000
| – | – | 0.01% | 1049 |
|
|
2018
Q3 | $21.6M | Hold |
61,000
| – | – | 0.01% | 1082 |
|
|
2018
Q2 | $17.7M | Sell |
61,000
-69,000
| -53% | -$19.4M | 0.01% | 1143 |
|
|
2018
Q1 | $35.6M | Sell |
130,000
-65,900
| -34% | -$20.5M | 0.02% | 728 |
|
|
2017
Q4 | $62.4M | Hold |
195,900
| – | – | 0.03% | 508 |
|
|
2017
Q3 | $61.3M | Buy |
195,900
+35,000
| +22% | +$10.4M | 0.03% | 463 |
|
|
2017
Q2 | $43.7M | Sell |
160,900
-48,900
| -23% | -$12.9M | 0.02% | 599 |
|
|
2017
Q1 | $57.4M | Buy |
209,800
+57,500
| +38% | +$16.3M | 0.03% | 454 |
|
|
2016
Q4 | $43.2M | Sell |
152,300
-35,000
| -19% | -$10.4M | 0.02% | 585 |
|
|
2016
Q3 | $58.6M | Buy |
187,300
+128,900
| +221% | +$38.2M | 0.03% | 440 |
|
|
2016
Q2 | $14.1M | Sell |
58,400
-8,400
| -13% | -$2.21M | 0.01% | 1204 |
|
|
2016
Q1 | $17.4M | Sell |
66,800
-5,400
| -7% | -$1.43M | 0.01% | 1012 |
|
|
2015
Q4 | $22.1M | Sell |
72,200
-19,400
| -21% | -$5.57M | 0.01% | 889 |
|
|
2015
Q3 | $26.7M | Buy |
91,600
+44,100
| +93% | +$14.6M | 0.02% | 617 |
|
|
2015
Q2 | $19.2M | Buy |
+47,500
| New | +$19.1M | 0.01% | 841 |
|
|
2014
Q4 | – | Sell |
-2,000
| Closed | -$662K | – | 6162 |
|
|
2014
Q3 | $662K | Buy |
+2,000
| New | +$659K | ﹤0.01% | 3193 |
|
|
2014
Q2 | – | Sell |
-1,000
| Closed | -$306K | – | 5922 |
|
|
2014
Q1 | $306K | Buy |
+1,000
| New | +$317K | ﹤0.01% | 3748 |
|
Other funds holding BIIB
VCM
VPM
Royal Bank of Canada's BIIB Position: Q1 2026 in Review
Royal Bank of Canada reduced its Biogen (BIIB) stake by 1.9% in Q1 2026, selling an estimated $1.93M and leaving 531,377 shares worth $97.4M. The position accounts for 0.02% of the portfolio, ranked #637.
Royal Bank of Canada first reported a position in BIIB in Q2 2013 and has held it in 52 quarters since. The position peaked at $177M in Q1 2018. 1,008 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Royal Bank of Canada held 531,377 shares of Biogen worth $97.4M as of Q1 2026.
- Royal Bank of Canada sold 10,448 Biogen shares in Q1 2026, an estimated $1.93M.
- Biogen made up 0.02% of Royal Bank of Canada's portfolio in Q1 2026, its #637 holding.
- Royal Bank of Canada first reported a position in Biogen in Q2 2013 and has held it in 52 quarters since.
- Royal Bank of Canada's Biogen position peaked at $177M in Q1 2018.
- 1,008 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.